Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party-Reference-Cited by-同舟云学术

Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party

Published:2007-05-01 Issue:11 Volume:96 Page:1644-1649
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Berghmans T, ,Lafitte J J,Lecomte J,Alexopoulos C G,Van Cutsem O,Giner V,Efremidis A,Berchier M C,Collon T,Meert A P,Scherpereel A,Ninane V,Leclercq N,Paesmans M,Sculier J P

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6603772.pdf

Reference25 articles.

1. Barlesi F, Jacot W, Astoul P, Pujol JL (2006) Second-line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer 51: 159–172

2. Buccheri G, Ferrigno D (2004) Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin. Lung Cancer 45: 227–236

3. Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, Isla D, Gonzalez JL, Almenar D, Blasco A, Rosell R, Carrato A, Vinolas N, Batista N, Giron CG, Galan A, Lopez M, Blanco R, Provencio M, Diz P, Felip E (2006) Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17: 467–472

4. Ceresoli GL, Gregorc V, Cordio S, Bencardino KB, Schipani S, Cozzarini C, Bordonaro R, Villa E (2004) Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. Lung Cancer 44: 231–239

5. Esteban E, Gonzalez de SL, Fernandez Y, Corral N, Fra J, Muniz I, Vieitez JM, Palacio I, Fernandez JL, Estrada E, Lacave AJ (2003) Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 14: 1640–1647

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance;Cancer Science;2022-06-24

2. Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer;Expert Opinion on Pharmacotherapy;2017-04-17

3. Transcutaneous electrical acupoint stimulation (TEAS) ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients;Journal of Thoracic Disease;2017-03

4. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer;Cancer Management and Research;2014-10

5. F2A sequence linking MGMTP140K and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells;Cancer Gene Therapy;2012-10-05